Bavarian Nordic (OTCMKTS:BVNRY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “

Separately, Maxim Group reaffirmed a “hold” rating on shares of Bavarian Nordic in a research note on Friday, September 15th.

Bavarian Nordic (BVNRY) remained flat at $$13.37 during trading hours on Monday. The stock has a market cap of $1,284.04 and a PE ratio of 37.14. The company has a current ratio of 2.87, a quick ratio of 2.70 and a debt-to-equity ratio of 0.01. Bavarian Nordic has a 1-year low of $10.44 and a 1-year high of $22.70.

Bavarian Nordic (OTCMKTS:BVNRY) last released its quarterly earnings results on Friday, August 25th. The company reported $0.07 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.14 by ($0.07). The firm had revenue of $58.68 million for the quarter, compared to the consensus estimate of $50.65 million. Bavarian Nordic had a return on equity of 11.16% and a net margin of 15.48%. sell-side analysts anticipate that Bavarian Nordic will post 0.19 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Bavarian Nordic (BVNRY) Raised to “Hold” at Zacks Investment Research” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at

About Bavarian Nordic

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus.

Receive News & Stock Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related stocks with our FREE daily email newsletter.